Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 11/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29305141 | 1.00 | KLKB1 (0.45) | KLKB1DGAT1METTL3LRRK2ALDH1A1 | |
| SCHEMBL29302884 | 0.94 | KLKB1 (0.41) | KLKB1DGAT1METTL3LRRK2 | |
| SCHEMBL29879497 | 0.94 | KLKB1 (0.41) | KLKB1DGAT1METTL3LRRK2 | |
| SCHEMBL29302883 | 0.90 | DGAT1 (0.42) | KLKB1DGAT1METTL3LRRK2 | |
| SCHEMBL29878984 | 0.90 | DGAT1 (0.42) | KLKB1DGAT1METTL3LRRK2 | |
| SCHEMBL24739924 | 0.88 | KLKB1 (0.41) | KLKB1DGAT1METTL3LRRK2 | |
| SCHEMBL29879770 | 0.88 | KLKB1 (0.41) | KLKB1DGAT1METTL3LRRK2 | |
| SCHEMBL29879922 | 0.88 | KLKB1 (0.40) | KLKB1DGAT1METTL3LRRK2 | |
| SCHEMBL24737576 | 0.88 | KLKB1 (0.40) | KLKB1DGAT1METTL3LRRK2 | |
| SCHEMBL29305133 | 0.87 | KLKB1 (0.42) | KLKB1DGAT1METTL3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | claimed |
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | KLKB1 1/4885DGAT1 986/4885METTL3 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.